START and Fundación Rioja Salud to expand access to cancer drug trials in Spain
The US-based START Center for Cancer Research (START) has signed a strategic collaboration with the Spanish Fundación Rioja Salud foundation…
All articles by
-
-
Shockwave Medical enrols all subjects in study of PCI to treat calcified lesions
US-based medical device company Shockwave Medical has finished enrolling subjects in the EMPOWER CAD study of percutaneous coronary intervention (PCI)…
-
Moderna and MSD begin trial of mRNA-4157 and Keytruda combination for lung cancer
Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in…
-
Maze Therapeutics reports positive data from Phase I AKD treatment trial
Maze Therapeutics has revealed positive outcome from the Phase I clinical trial in healthy volunteers assessing oral MZE829, being developed…
-
Lilly’s EBGLYSS shows improvement in Phase IIIb study for atopic dermatitis
Eli Lilly's EBGLYSS has demonstrated improvement in skin condition and itch relief in patients with moderate-to-severe atopic dermatitis, according to…
-
Novartis’ Fabhalta shows positive outcomes in C3 glomerulopathy treatment
Novartis has announced positive results from the Phase III APPEAR-C3G study, indicating that Fabhalta (iptacopan), when combined with supportive care,…
-
Intellia reports positive data from Phase II study of NTLA-2002 for HAE
Intellia Therapeutics has reported positive results from its ongoing Phase I/II trial of NTLA-2002, a CRISPR-based gene editing therapy for…
-
Marinus’ clinical trial of ganaxolone fails to meet primary endpoint
Marinus Pharmaceuticals has reported that the Phase III TrustTSC trial of oral ganaxolone in treating seizures linked to tuberous sclerosis…
-
ImmunityBio commences CD19 t-haNK cell therapy trial for NHL
ImmunityBio has announced the commencement of a Phase I clinical trial evaluating its CD19 targeted high-affinity natural killer (t-haNK) cell…
-
OKYO Pharma doses first subject in OK-101 Phase II trial for NCP
OKYO Pharma has initiated the Phase II trial of OK-101, a treatment for neuropathic corneal pain (NCP), by dosing the…